Reports indicate that TMB in BRAF‐altered MBC is generally higher, and hence may be a potential biomarker of ICPI efficacy, but larger studies are lacking with regard to the predictive status of BRAF mutations in breast cancer. This evidence concerns the gene BRAF and breast cancer.